<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00107913</url>
  </required_header>
  <id_info>
    <org_study_id>HOS1</org_study_id>
    <nct_id>NCT00107913</nct_id>
  </id_info>
  <brief_title>Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura</brief_title>
  <official_title>Phase II Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hematology and Oncology Specialists</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hematology and Oncology Specialists</source>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and safety of single agent Doxil in the
      treatment of patients with refractory ITP (Idiopathic Thrombocytopenic Purpura).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will receive Doxil 20 mg/m2 IV over 1 hour every 2 weeks. Treatment will be
      continued for 1 course beyond return of the platelet count to normal with a maximum of 18
      courses.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2001</start_date>
  <completion_date>April 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the primary outcome would be a platelet response, with a return of platelet count to normal</measure>
  </primary_outcome>
  <enrollment>10</enrollment>
  <condition>Autoimmune Thrombocytopenic Purpura</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Thrombocytopenia with bone marrow findings showing normal or increased numbers of
             megakaryocytes.

          -  Failure to respond to initial treatment with steroids, IV immune globulin, splenectomy
             and post splenectomy steroids.

          -  Platelet count of 30,000 or less.

          -  Performance status score of 2 or less.

          -  Adequate organ function: *bilirubin&lt; 2; *AST &lt; 3 times normal; *creatinine &lt; 2.

          -  No prior treatment with anthracycline or chemically related drugs.

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  Presence of a malignancy other than basal cell carcinoma of the skin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas M Cosgriff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology and Oncology Specialists</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hematology and Oncology Specialists</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Ann Ostroske, RN</last_name>
      <phone>504-894-7115</phone>
      <phone_ext>221</phone_ext>
      <email>mostroske1@salco.net</email>
    </contact>
    <contact_backup>
      <last_name>Avri Haggerty, MT</last_name>
      <phone>504-883-2968</phone>
      <email>ahaggerty@salco.net</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas M Cosgriff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2005</study_first_submitted>
  <study_first_submitted_qc>April 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2005</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Immune Thrombocytopenic Purpura</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

